| HOME >> MEDICINE >> TECHNOLOGY |
Detailed Data from the Phase 3 Glufosfamide and Phase 2 Glufosfamide Plus
Gemcitabine Clinical Trials to be Presented
REDWOOD CITY, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced two presentations regarding its oncology product candidate glufosfamide. The presentations will take place at the 2007 European Cancer Conference (ECCO) being held September 23 to 27, 2007, at the International Conference Center in Barcelona, Spain.
As announced on February 26, 2007, the Phase 3 trial of glufosfamide showed that the overall survival in patients with metastatic pancreatic cancer who had relapsed after gemcitabine chemotherapy was 18% higher in the glufosfamide arm compared to those who received best supportive care (BSC), but the result did not reach statistical significance. Detailed analysis of the data from that study suggests that glufosfamide is active in certain subgroups of patients. The Company believes that additional clinical investigation of these subgroups is warranted. These data and subgroups will be described during the oral presentation on September 27.
The following oral presentation will take place:
Glufosfamide (GLU) in metastatic pancreatic adenocarcinoma previously treated with gemcitabine: Results of a Phase 3 trial.
Gastrointestinal malignancies -- noncolorectal cancer, Room 111 Thursday, September 27, 2007 at 10:15am
As announced on December 27, 2006, the response rate for the Phase 2
glufosfamide plus gemcitabine front-line pancreatic cancer trial was 21%
(including one unconfirmed partial response). The detailed results of the
Phase 2 trial, including complete 12-month survival data, will be
'/>"/>
| SOURCE Threshold Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |